EXHIBIT 99.1

         IMAGING DIAGNOSTIC SYSTEMS REPORTS STRONG FIRST QUARTER REVENUE

                        Record Five CTLM(R) Systems Sold


Fort Lauderdale, Florida, October 12, 2005--Imaging Diagnostic Systems, Inc.,
(OTCBB: IMDS) reported today that a record five CT Laser Mammography (CTLM(R))
systems were sold in the quarter ending September 30, 2005.

In the quarter ending September 30, 2005, IDSI is expected to report net sales
of $671,750, up from the $374,952 reported for the entire previous fiscal year
ending June 30, 2005.

"Our first fiscal quarter was a clear endorsement of the effectiveness of our
global commercialization program and growing market acceptance of laser breast
scanning. Four of the five sales had been announced via press releases; details
of the fifth will soon be released. We are gaining traction in several key
geographic areas as our distributors and clinical partner sites gain experience
with this new technology. It is an exciting time," stated Tim Hansen, IDSI Chief
Executive Officer.

The CTLM(R) system is the first patented breast imaging system that utilizes
state-of the-art laser technology and patented algorithms to create 3-D cross-
sectional images of the breast. It is a non-invasive, painless examination that
does not expose the patient to radiation or require breast compression. Imaging
Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License,
China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA
export certification for its CT Laser Breast Imaging system. The Company is
seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for
its CTLM(R) system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: www.imds.com for additional
information.


In conjunction with the provisions of the Safe Harbor section of the Private
Securities Litigation Reform Act of 1995, this news release may contain
forward-looking statements pertaining to future anticipated projected plans,
performances and developments, as well as other statements relating to future
operations. All such forward-looking statements are necessarily only estimates
of future results and there can be no assurance that actual results will not
materially differ from expectation. Further information on potential factors
that could affect Imaging Diagnostic Systems, Inc., is included in the Company's
filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
----------------------